...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients.
【24h】

Pharmacokinetics and Dosage Adaptation of Meropenem during Continuous Venovenous Hemodiafiltration in Critically Ill Patients.

机译：美罗培南在重症患者连续静脉血液透析滤过期间的药代动力学和剂量适应。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Meropenem, a carbapenem broad-spectrum antibiotic, is regularly used in patients undergoing continuous venovenous hemodiafiltration (CVVHDF). Its disposition was studied over one dosage interval in 15 patients under CVVHDF on a steady regimen of 500 or 1000 mg every 8 to 12 hours. Meropenem levels were measured in plasma and filtrate-dialysate by high-performance liquid chromatography (HPLC) with UV detection. The mean CVVHDF flow rates were 7.1 +/- 0.9 L/h for blood (mean +/- SD), 0.5 +/- 0.3 L/h for predilution solution, 1.2 +/- 0.3 L/h for countercurrent dialysate, and 1.8 +/- 0.5 L/h for the total filtrate-dialysate. The pharmacokinetic analysis was based both on a noncompartmental approach and on a four-compartment modeling. The mean (coefficient of variation [CV]) total body clearance, volume of distribution at steady state, and mean residence time were, respectively, 5.0 L/h (46%), 14.3 L (29%), and 4.8 h (36%). The hemodiafiltration clearances calculated from plasma data alone and plasma with filtrate-dialysate data were 1.2 L/h (26%) and 1.6 L/h (39%), respectively. The compartmental model was used to optimize the therapeutic schedule of meropenem, considering reference minimal inhibitory concentration (MIC) of sensitive strains (4 mg/L). The results indicate that two different therapeutic schedules of meropenem are equally applicable to patients receiving CVVHD: either 750 mg tid or 1500 bid.
机译：美洛培南是碳青霉烯广谱抗生素，通常用于接受连续静脉血液透析滤过（CVVHDF）的患者。在15个CVVHDF下的患者中，以每8至12小时500或1000 mg的稳定剂量研究了其剂量分布。通过高效液相色谱（HPLC）和紫外线检测，测定血浆和滤液透析液中美罗培南的水平。血液的CVVHDF平均流速为7.1 +/- 0.9 L / h（平均+/- SD），预稀释液为0.5 +/- 0.3 L / h，逆流透析液为1.2 +/- 0.3 L / h和1.8总滤液透析液的+/- 0.5 L / h。药代动力学分析基于非隔室方法和四隔室模型。平均总体清除率（变异系数[CV]），稳态下的分布量和平均停留时间分别为5.0 L / h（46％），14.3 L（29％）和4.8h（36） ％）。仅从血浆数据和含滤液透析液数据的血浆计算出的血液透析滤过率分别为1.2 L / h（26％）和1.6 L / h（39％）。考虑到敏感菌株的参考最小抑菌浓度（MIC）（4 mg / L），使用区室模型优化美罗培南的治疗方案。结果表明，美洛培南的两种不同的治疗方案同样适用于接受CVVHD的患者：750 mg tid或1500 bid。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号